TOBRADEX [tobramycin/dexamethasone] ophthalmic suspension versus tobramycin 0.3 percent/dexamethasone 0.05 percent ophthalmic suspension.

Trial Profile

TOBRADEX [tobramycin/dexamethasone] ophthalmic suspension versus tobramycin 0.3 percent/dexamethasone 0.05 percent ophthalmic suspension.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2010

At a glance

  • Drugs Dexamethasone; Tobramycin; Tobramycin/dexamethasone
  • Indications Bacterial infections; Blepharoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 15 Jan 2010 Actual end date (March 2008) added as reported by ClinicalTrials.gov.
    • 15 Jan 2010 Actual patient number (221) added as reported by ClinicalTrials.gov.
    • 24 Mar 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top